Unsafe in porphyria. Caution when used in patients with epilepsy; Parkinson's disease; narrow angle glaucoma; prostatic hypertrophy; hypothyroidism; hyperthyroidism; liver disease; cardiac disease or arrhythmias; severe respiratory disease; renal failure; myasthenia gravis; phaeochromocytoma. Patients with hypersensitivity to thioxanthenes or other antipsychotics. Close monitoring for changes in behaviour, suicidal thoughts or clinical worsening during the initial part of the treatment is recommended. May impair control of
diabetes; monitor blood glucose in diabetics.
Drowsiness, dry mouth, constipation, vomiting, dyspepsia,
diarrhea, abdominal pain, nausea, flatulence. Extrapyramidal effects, especially in the initial phase of the treatment.
Tachycardia, palpitations, prolonged QT interval,
hypotension.
Thrombocytopenia,
neutropenia,
leukopenia,
agranulocytosis.
Dyspnoea,
myalgia, muscle rigidity, micturition disorder, urinary retention. Increased appetite and weight. Abnormal glucose tolerance and LFTs.
Insomnia, depression, nervousness,
agitation, decreased libido,
Tardive dyskinesia. ==Drug Interactions==